media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Application for drug registration and marketing authorization of dapagliflozin tablets accepted

People’s Finance News, July 27 – Saisheng PharmaceuticalOn July 27, (300485) announced that its subsidiary, Saier Biotech, recently received an “Acceptance Notice” from the National Medical Products Administration (NMPA) for its application for registration and marketing authorization of dapagliflozin tablets for domestic production. This drug lowers blood sugar by inhibiting renal tubular glucose reabsorption and promoting urinary glucose excretion. Monotherapy carries a low risk of hypoglycemia, does not cause weight gain, has mild gastrointestinal reactions, and may protect pancreatic β-cell function by reducing glucotoxicity. https://finance.eastmoney.com/a/202607273822093693.html
- Source: drugdu
- 73
- July 31, 2026
China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market

On July 27, China Biopharmaceutical (01177) announced that it had signed a joint venture agreement with Indonesian listed company PT Tempo Scan Pacific Tbk (Tempo Scan) to jointly establish a joint venture company PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI). Sino Biopharmaceutical holds a 51% stake in TCBI, while Tempo Scan holds a 49% stake. The joint venture will combine Sino Biopharmaceutical’s strengths in innovative R&D and product pipeline with Tempo Scan’s localized capabilities in Indonesia, including manufacturing, regulatory registration, market access, sales and marketing, and distribution networks. The announcement stated that both parties are currently advancing multiple specialty drugs and innovative drugs.The registration and listing process has been completed, with some products already approved and several others under review. In addition to commercial cooperation, both parties will continue to explore further cooperation opportunities, including academic exchanges, local clinical development, production technology transfer, and future localized production. The establishment of the ...
- Source: drugdu
- 79
- July 31, 2026
Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved

People’s Finance News, July 30th – Changchun High & New Technology Industries Group Co., Ltd.(000661) announced on July 30 that its subsidiary, Jinsai Pharmaceutical, recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, and the application for registration of the domestic production of GenSci144 tablets by Jinsai Pharmaceutical has been approved. GenSci144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6A19, independently developed by Jinsai Pharmaceutical. It is registered as a Class 1 chemical drug and is intended for the treatment of chronic kidney disease (CKD). https://finance.eastmoney.com/a/202607303826738322.html
- Source: drugdu
- 63
- July 31, 2026
Degludec Insulin Injection Receives Marketing Approval

On July 30, Dongyangguang Pharmaceutical (06887) announced that its independently developed insulin degludec injection has received marketing approval from the National Medical Products Administration (NMPA). The drug is available in both cartridge and pre-filled injection pen versions. Insulin degludec injection is a fourth-generation long-acting basal insulin analog with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, allowing for once-daily dosing to meet the entire day’s basal insulin requirements. Furthermore, this drug is superior to insulin glargine in terms of glucose-lowering curve stability and the incidence of hypoglycemia. With the launch of insulin degludec injection, the company now offers six insulin products in the Chinese market, covering three major clinical application scenarios: basal, prandial, and premixed insulin. The company is also pursuing international registration for other insulin products to expand its international market share. https://finance.eastmoney.com/a/202607303826929962.html
- Source: drugdu
- 68
- July 31, 2026
【EXPERT Q&A】What are the requirements for the approval of medical device qualifications?

Drugdu.com expert’s response: I. Basic Eligibility for Applicants To apply for medical device export qualification approval in China, the applicant must be a domestic medical device registrant, filing entity, or a manufacturer that has obtained the Medical Device Production License or completed production filing. Its registered business address must fall within the administrative jurisdiction of the approving authority. Applications will be rejected if the enterprise is under ordered rectification for production suspension, included in the serious illegal and dishonest list, or the relevant product is under ongoing investigation. II. Document Requirements for Two Types of Export Qualifications For medical devices that have completed registration or filing in China, the required documents include the corresponding Medical Device Registration Certificate or product filing record, the supporting Medical Device Production License or production filing record, and valid documents proving the product’s legal sales status. For export-specific medical devices that have not completed domestic ...
- Source: drugdu
- 101
- July 31, 2026
Changchun Medical Exhibition Organizing Committee

Organiser：Weilian Exhibitions Time：August 15th – 17th, 2026 Address：No.100, Huizhan Street, Economic Development Zone, Changchun City, Jilin Province Exhibition hall：Changchun International Convention & Exhibition Center Product range: Medical Imaging‌: CT, DR radiology equipment, ultrasound imaging equipment, medical X-ray equipment, magnetic resonance equipment, nuclear medicine equipment, medical optical equipment, medical films and interventional products, etc. ‌Medical Electronics‌: Functional examination equipment, endoscopy examination equipment, pathological diagnosis equipment, cardio-encephalomyoelectric diagnostic equipment, monitoring instruments, respiratory equipment, anesthesia and pain relief equipment, laser equipment, low-temperature refrigeration equipment, first-aid equipment, etc. ‌In-vitro Diagnosis & Laboratory Medicine‌: Clinical diagnostic equipment, diagnostic reagents, biochemical testing equipment, POCT, overall laboratory solutions, biochemical analyzers, chromatographic analyzers, clinic analyzers, home diagnostic equipment, etc. ‌Operating Room Equipment & Surgical Instruments‌: Integrated operating room solutions, anesthesia machines, ventilators, monitors, operating tables, shadowless lamps, pendant systems, surgical instruments, electrosurgical units and consumables, staplers, suturing devices, suture needles/threads, laser surgical instruments, ultrasonic surgical equipment, operating ...
- Source: drugdu
- 87
- July 30, 2026
【EXPERT Q&A】When an overseas buyer sends an inquiry, how should the first sentence be replied to?

Drugdu.com expert’s response: When engaging in pharmaceutical foreign trade, many suppliers encounter this situation: You receive an overseas inquiry. The buyer only writes one sentence: “Please send me your price.” or “We are interested in your product.” Upon seeing the inquiry, many enterprises’ first reaction is to quote immediately. However, after sending the quotation, a common problem arises: the buyer does not follow up. Why? Because in the first round of communication, the supplier and the buyer may focus on different things. What the buyer wants to confirm is: Whether this product meets their needs? Whether the supplier has export experience? Can relevant documents be provided? Is the price suitable for their market? Yet suppliers often only focus on: When will the customer place an order? Therefore, the first response to an overseas inquiry is not just to reply to the customer, but more importantly, to initiate effective communication. I‌. Do not ...
- Source: drugdu
- 93
- July 29, 2026
China International Medical Instrument & Equipment Exhibition – Beijing Health Conference (China-Hospeq)

Organiser：International Exchange and Cooperation Center of the National Health Commission Time：August 14th – 16th, 2026 Address：No.7 Tianchen East Road, Aoyuncun Sub-district, Chaoyang District, Beijing Exhibition hall：China National Convention Center Product range: Large Imaging and X-ray Equipment: General and dedicated digital/conventional X-ray diagnostic systems, X-ray stereotactic therapy systems (X-knife), gamma ray stereotactic therapy systems, medical accelerators, CT scanners, MRI systems, SPECT, PET scanners Ultrasound Equipment: Color/black-and-white ultrasonic diagnostic systems, high-intensity focused ultrasound devices Medical Informatics: PACS, HIS, RIS, Continua Health Alliance devices, HE-C testing systems Emergency & Operating Room Equipment: ECG machines, monitors, cardiac defibrillators/pacemakers, ventilators, anesthesia machines, heart-lung machines, medical lasers, electrosurgical units, minimally invasive surgical devices, blood transfusion equipment, shadowless lamps, operating tables Endoscopes: Rigid endoscopes, fiber-optic endoscopes, electronic ultrasonic endoscopes Clinical Laboratory & Medical Lab Equipment: Centrifuges, biochemical analyzers, blood/urine testing devices, bacterial culture & identification systems, pathological sectioning/staining/analysis equipment; lab instruments including balances, test chambers, biomedical ...
- Source: drugdu
- 118
- July 28, 2026
The king of valves’ revenue exceeded expectations, with TMTT surging by 47%!

Edwards Life Sciences recently announced its second-quarter results, with revenue of $1.74 billion, a 13.6% year-over-year increase, representing a significant growth.However, it’s worth noting that net profit performance contrasts sharply with revenue growth. Net profit for the period was $241.9 million, a 27.4% year-over-year decline. Nevertheless, looking at each business segment, Edwards’ core business remains solid. As Edwards’ core business, transcatheter aortic valve replacement (TAVR) sales reached $1.3 billion in the second quarter, up 11.3% year-over-year. This business accounts for approximately 75% of the company’s total revenue and remains its absolute pillar. Edwards attributed the growth of TAVR to continued clinical momentum and evidence-based support for active disease management of aortic stenosis. The company specifically highlighted the differentiated advantages of its Sapien TAVR platform, namely the 7-year follow-up data from the PARTNER 3 trial presented at the recent New York Heart Valve Conference, and the latest findings from the EARLY ...
- Source: drugdu
- 93
- July 27, 2026
A neurosurgical robotics company has officially announced its latest appointment!

AiM Medical Robotics recently announced the appointment of Andrew “Andy” Aberdale as the company’s new president and chief financial officer. Founded in 2018, AiM Medical Robotics is a company focused on neurosurgical robots, dedicated to developing surgical robot technologies that enable precise neurosurgical procedures to be performed directly under magnetic resonance imaging. Its platform utilizes a combination of intraoperative real-time magnetic resonance imaging and robot guidance in neurosurgical systems to ensure precise implantation of neurostimulation electrodes for Parkinson’s disease patients. The platform has also been extended to a range of craniocerebral surgeries, such as biopsies, tumor ablation, and targeted intracranial delivery of novel therapies. It is understood that Andy, the newly appointed leader, has over thirty years of experience in operations and finance leadership. His past experience includes successfully commercializing early-stage startups and achieving smooth exits, as well as executing high-value exits and driving rapid organizational growth. According to the ...
- Source: drugdu
- 91
- July 27, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.